Yael L. Maxwell

Some argue new trial designs or devices are needed in this space; others say using cerebral embolic protection is “wishful thinking.”

Specialty technologies are still needed for select patients, but balloons can do the job with “meticulous” planning and imaging.

Logistical challenges may impede heparin pretreatment by emergency personnel and complicate communications.

(UPDATED) Specialty technologies are still needed for select patients, but balloons can do the job with “meticulous” planning and imaging.

With the data under review by the FDA, experts estimate that a substantial population could potentially benefit.

Several experts argue that AI-QCA is not a replacement for OCT, but could be valuable in low-resource settings.

With further refinement and defined thresholds for treatment, this technology has the potential to guide treatment decisions.

No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

The STS/ACC TVT Registry data should alleviate prior concerns about the appropriateness of choosing TAVI for young patients.

The latest version of the LLM had high concordance with a multidisciplinary heart team in choosing between PCI and CABG.